Heterocyclic compounds and compositions as inhibitors of kinases and PDGFR C-KIT INHIBITORS

A compound of formula I: wherein: R1 is selected from halogen, C1-6 alkyl, C3-12 cycloalkyl, C3-8 heterocycloalkyl, C6-10aryl and C3-10heteroaryl; inthe said C1-6alkyl of R1 is optionally substituted with 1 to 3 radicals independently seleccionadosde halogen, hydroxyl, cyano, nitro,> = N (OH), C14 alkoxy and benzoxy; wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl of R1 is optionally substituted with 1 to 3 radicals independently selected dehalogeno, hydroxyl, cyano, nitro, C1-6 alkyl, C1-6 halogenosustituido alkyl, C1-6 hydroxy-alkyl, alkoxy C1 -6, C1-6alkoxy halogenosustituido, -X1NR3aR3b, -X1C (O) R3a, -X1C (O) OR3a, -X1OR3a, C3-12cycloalkyl, C3-8heterocycloalkyl, C6-10aryl and C3-10heteroaryl; wherein X1 is selected from a bond and C1-4alkylene; in losque R3a and R3b are independently selected from hydrogen and C1-6alkyl; R2 is selected from methyl and ethyl; A is an unsaturated ring members containing 2 or 3 heteroatoms or groups selected from> = N-, -NR4-, -O- and -S (O) 0-2-; wherein R4 is selected from hydrogen, C1-4alkyl and C3-8cycloalkyl; wherein said C1-4 alkyl C3-8 ocicloalquilo of R4 can have a methylene replaced by a heteroatom selected from O, S (O) 0-2 and NR30; where R30 is selected from hydrogen and C1-4alkyl; wherein A may be optionally substituted C1-2 conalquilo; or pharmaceutically acceptable salts and solvates thereof.